Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 30, 2015 9:09 AM ET


Company Overview of 3SBio Inc.

Company Overview

3SBio Inc. offers research and development, manufacture, and marketing of bio-pharmaceutical products. Its principal products include EPIAO, an injectable recombinant human erythropoietin to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions; and TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombocytopenia. The company also markets Intefen, a recombinant interferon alpha-2a product to treat carcinoma and viral infectious diseases; Inleusin, a recombinant human interleukin-2 product to treat renal cell carcinoma, metastatic melanoma, and thoratic fluid build-up caused by cancer and tuberculosis; Iron Su...

No. 3 A1, Road 10

Shenyang Economy & Technology Development Zone

Shenyang,  110027


Founded in 2006

891 Employees


86 24 2538 6000

Key Executives for 3SBio Inc.

Co-Founder, Chairman, Chief Executive Officer, Chairman of Nominating Committee and Member of Investment Committee
Age: 51
Co Founder and Advisor
Age: 78
Chief Financial Officer, Principal Accounting Officer and Member of Investment Committee
Age: 41
Chief Technology Officer, Vice President of R&D and Director
Age: 44
Vice President and Corporate Secretary
Age: 46
Compensation as of Fiscal Year 2014.

3SBio Inc. Key Developments

3SBio Seeks Acquisitions

3SBio Inc. filed an IPO in the amount of HKD 5.5 billion. It will use the proceeds to fund acquisitions and recruit staff to help it grab a bigger piece of the booming Chinese drug market.

3SBIO Launches IPO

3SBIO Inc. launches an IPO of HKD 712 million IPO in Hong Kong to fund acquisitions and recruit staff to help it grab a bigger piece of the booming Chinese drug market. 3SBIO plans to use 45%of the IPO proceeds to expand its portfolio of drugs through acquisitions, 15% to hire more sales staff and open offices around China, and another 15% for new production lines. The remainder would be spent on research and development and working capital.

3SBio Signs Exclusive Patent License Agreement for DIG-KT With PharmAbcine, Inc

3SBio Inc. announced that it has entered into an exclusive licensing deal with PharmAbcine Inc. for the development, manufacturing and marketing of DIG-KT, a bi-specific monoclonal antibody (mAb) targeting both VEGFR2/KDR and Tie-2 pathways for cancer in the territory of Greater China (including mainland China, Taiwan, Hong Kong and Macau) and Korea.

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact 3SBio Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at